Dr Ignacio Gil-Bazo speaks to ecancer at the Best of ASCO®️ 2024 Miami Symposium about a talk he presented on biomarkers, predictive and prognostic factors of resistance to immunotherapy.

He highlights several trials from this year’s ASCO with a focus on CtDNA detection - which has become a new standard in biomarkers.

Dr Gil-Bazo particularly highlights the Checkmate-816 trial which evaluated the combination of nivolumab with chemotherapy. 

He explains that in this trial patients who were able to completely clear CtDNA at cycle 7 were the patients who showed greater benefit with overall survival and progression free survival.